CRISPR Therapeutics AGCRSPNASDAQ
LOADING
|||
Switch Symbol:
Net Income Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year net income growth rate
Latest
48.96%
↑ 110% above average
Average (39q)
-501.07%
Historical baseline
Range
High:770.91%
Low:-20170.92%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 48.96% |
| Q2 2025 | -53.35% |
| Q1 2025 | -264.49% |
| Q4 2024 | 56.59% |
| Q3 2024 | 32.01% |
| Q2 2024 | -8.42% |
| Q1 2024 | -230.49% |
| Q4 2023 | 179.67% |
| Q3 2023 | -44.27% |
| Q2 2023 | -46.50% |
| Q1 2023 | 52.01% |
| Q4 2022 | 36.65% |
| Q3 2022 | 6.07% |
| Q2 2022 | -3.69% |
| Q1 2022 | -26.88% |
| Q4 2021 | -11.09% |
| Q3 2021 | -116.75% |
| Q2 2021 | 770.91% |
| Q1 2021 | -5.72% |
| Q4 2020 | -15.79% |
| Q3 2020 | -16.05% |
| Q2 2020 | -14.23% |
| Q1 2020 | -328.31% |
| Q4 2019 | -77.94% |
| Q3 2019 | 357.78% |
| Q2 2019 | -10.93% |
| Q1 2019 | -1.72% |
| Q4 2018 | 6.15% |
| Q3 2018 | -32.13% |
| Q2 2018 | -35.62% |
| Q1 2018 | -20170.92% |
| Q4 2017 | 100.57% |
| Q3 2017 | -10.72% |
| Q2 2017 | -3.91% |
| Q1 2017 | -225.60% |
| Q4 2016 | 216.36% |
| Q3 2016 | 14.39% |
| Q2 2016 | -103.32% |
| Q1 2016 | 31.29% |
| Q4 2015 | -93.36% |